AcroMeta Group Limited (SGX: 43F) has announced a strategic move into the emerging field of ambient temperature cellular logistics (ATCLS), signing a non-binding term sheet with Macro HRD SG Pte. Ltd. (Macro), a Singapore-based healthcare consultancy. Under the proposed partnership, AcroMeta would acquire a strategic stake in Macro-ATCLS Pte. Ltd., the entity commercializing Macro's ATCLS technology, and holds an option to secure an exclusive license to deploy the technology across Southeast Asia.

The ATCLS technology aims to transform the transportation of living cells and temperature-sensitive biological materials by removing reliance on conventional cold chains. It employs proprietary ambient-temperature preservation and reactivation methods, supported by a Gradient Equilibrium Decision Modeling (GEDM) platform for real-time governance and control. Dormant cells can be shipped at ambient temperatures and reactivated at the point of use, potentially reducing the costs, fragility, and geographic limitations of current logistics.

Cold-chain dependency has long been a bottleneck in advanced therapeutics: CAR-T cells, stem cells, and other living biologics typically must be kept within narrow temperature ranges using liquid nitrogen dry shippers or validated refrigerated containers, and excursions during transit can compromise product viability. In Southeast Asia, where infrastructure for such logistics varies widely across markets, a solution that removes the cold chain entirely could expand the geographic reach of cell-based treatments to locations where cryogenic transport is impractical.

The initiative targets rapidly expanding markets, including stem cells, CAR-T/immune-cell therapy, gene therapy, regenerative medicine, and organ transplantation. According to Macro's management, the global cell-and-gene-therapy 3PL market was estimated at US$1.81 billion in 2025 and is projected to reach US$16.95 billion by 2035, representing a 25.1% compound annual growth rate. The serviceable addressable market for ATCLS is estimated at US$14.5 billion by 2032.

Lawrence Toh, Executive Director of AcroMeta, stated: "This proposed strategic partnership gives us the opportunity to build a position in an industry where cell and gene therapy logistics are expected to grow at double-digit rates in the years ahead. We see this as a natural extension of our strategy to grow our portfolio beyond our core operations."

The exclusive licensing arrangement for Southeast Asia would grant AcroMeta rights to develop and commercialize the technology in agreed territories, including the right to appoint sub-licensees and a first right to acquire additional territories, which could significantly expand the Group's commercial reach.

AcroMeta, currently operating in facility management services, plans to continue evaluating strategic opportunities for long-term growth and value creation for shareholders, emphasizing disciplined capital allocation as it enters this next phase.

The information regarding market projections was provided by Macro's management and has not been independently verified by AcroMeta's board, which has not audited the data.

The partnership positions AcroMeta to address the growing demand for specialized logistics in cell and gene therapies. By adopting ATCLS, the company could offer a solution that addresses the high costs and complexity of traditional cold-chain logistics, potentially making advanced therapies more accessible and affordable in Southeast Asia.

As the term sheet is non-binding, the transaction remains subject to due diligence, negotiation of definitive agreements, and satisfaction of conditions typically applicable to such transactions, including any required regulatory and shareholder approvals. The companies have not disclosed a timeline for finalizing the definitive agreements or the size of the contemplated strategic stake.

For more information on AcroMeta, visit www.AcroMeta.com. The original press release is available at www.newmediawire.com.